Case Report: Pulmonary enteric adenocarcinoma harboring KRAS/TP53/APC mutations with contralateral lung metastasis: diagnostic challenges and molecular insights.

Mengjie Mao, Mengling Hu, Qingxiu Tao, Zhuo Zuo, Bin Liu

Abstract readCase Reports

In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Editorial: Innovative ways of targeting the RTK/RAS/RAF pathway.Frontiers in oncology · 2026
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mengjie MaoSchool of Medical and Life Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu, China.

Mengling HuSchool of Medicine, University of Electronic Science and Technology of China, Chengdu, China.

Qingxiu TaoSchool of Medicine, University of Electronic Science and Technology of China, Chengdu, China.

Zhuo ZuoDepartment of Pathology, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China.

Bin LiuDepartment of Medical Oncology, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pulmonary enteric adenocarcinoma (PEAC) is a rare subtype of lung adenocarcinoma characterized by intestinal differentiation. We report a case of synchronous bilateral PEAC in an elderly male patient, a presentation that is rarely documented in the literature. Histopathological examination revealed glandular structures resembling colorectal adenocarcinoma, with immunohistochemical positivity for CDX2, CK20, and SATB2, and negativity for TTF-1 and CK7. Molecular testing identified concurrent KRAS, TP53, and APC mutations, suggesting the activation of a colorectal-like oncogenic pathway. Following surgical resection and adjuvant chemoradiotherapy, the patient achieved short-term disease stability. This case highlights the diagnostic dilemma between primary PEAC and metastatic colorectal cancer and underscores the importance of integrated molecular and immunophenotypic profiling for accurate classification and potential targeted therapy.

Indexed as

immunohistochemistryKRASPEACsynchronous bilateral lung cancerTP53

Identifiers

PMID41561768

DOI10.3389/fonc.2025.1726695

PMCPMC12812567

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.